<?xml version="1.0" encoding="UTF-8"?>
<p>COVID-19 severity is associated with liver diseases such as cirrhosis, non-alcoholic fatty liver disease, alcohol-related liver disease and chronic viral hepatitis and the presence of the virus in liver has been confirmed in pathological studies in patients with SARS [
 <xref rid="B23-medicina-56-00386" ref-type="bibr">23</xref>]. Patients having COVID-19 showed liver comorbidities and in these patients there were altered levels of AST and ALT. Patients also showed diminished serum albumin levels and elevated serum bilirubin levels [
 <xref rid="B24-medicina-56-00386" ref-type="bibr">24</xref>]. The direct viral infection of liver cell may be the cause of liver damage [
 <xref rid="B25-medicina-56-00386" ref-type="bibr">25</xref>]. There is also an elevation of gamma glutamyl transferase, which is a diagnostic biomarker for cholangiocyte injury [
 <xref rid="B24-medicina-56-00386" ref-type="bibr">24</xref>]. This suggests that ACE2 receptor expression may be enhanced in cholangiocytes and SARS-CoV-2 might bind to ACE2-positive cholangiocytes to alter the control of the liver function [
 <xref rid="B26-medicina-56-00386" ref-type="bibr">26</xref>].
</p>
